Related Articles
Optimal duration of whole body hyperthermia when combined with cis-diamminedichloroplatinum(II)
MODULATION OF [CIS-DIAMINEDICHLOROPLATINUM(II) HYPERTHERMIA] THERAPY BY INHIBITORS OF ARACHIDONIC-ACID METABOLISM
Enhancement of sensitivity to CDDP in human pharyngeal carcinoma cells by H-7, a protein kinase inhibitor
Influence of induction of HSP70 on the cytotoxicity of oxazaphosphorine compounds and cisplatin
Tumor oxygenation after hyperthermia in the rat 13762 mammary carcinoma and the DU-145 human prostate carcinoma